Unlock the therapeutic potential of targeted
protein degradation

NEOsphere Biotechnologies integrates world-class mass spectrometry with expert data analysis to systematically create broad pipelines of novel degrader targets at scale and advance our partners’ targeted protein degradation (TPD) drug discovery programs at every stage.

DEEP PROTEOMIC
SCREENING

Perform unbiased, proteome-wide
high-throughput screening of
entire degrader libraries with unmatched speed,
precision, and coverage to access
previously undruggable targets.
Deep Proteomic Screening characterizes
all types of degraders, and uncovers
novel TPD mechanisms.

TARGET
VALIDATION

Apply global ubiquitinomics to capture
target modifications with exceptional
depth and speed, and to gain a comprehensive
understanding of dynamic ubiquitin
signaling at the systemic level.

NEOVERSE
 

Effortlessly transform large-scale proteomic
data into actionable insights that inform
drug discovery decisions in SAR-optimization,
target identification, and library
expansion and optimization.

Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.